Completing genetic analysis of the ABCA4 locus
完成 ABCA4 位点的遗传分析
基本信息
- 批准号:8024019
- 负责人:
- 金额:$ 65.96万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-04-01 至 2015-03-31
- 项目状态:已结题
- 来源:
- 关键词:1p21AddressAllelesClinicalClinical TrialsCodeCopy Number PolymorphismDNA ResequencingDiagnosisDiseaseDisease modelExonsFamilyFunctional RNAGene MutationGenesGeneticGenetic DatabasesGenetic DeterminismGenetic ResearchGenetic VariationGenomeGenomicsGenotypeGoalsHeterogeneityMethodsMutationMutation DetectionOpen Reading FramesOutcome StudyPatientsPhenotypePoint MutationPopulationResearchResidual stateRestRetinal DegenerationRetinal DiseasesRetinitis PigmentosaScreening procedureStargardt&aposs diseaseTechnologyTestingVariantcohortdisease diagnosisdisease phenotypedisease-causing mutationexhaustexomegenetic analysisgenetic variantmutantnext generationnoveloutcome forecastprogramssegregation
项目摘要
DESCRIPTION (provided by applicant): Mutations in the ABCA4 gene are responsible for a wide variety of retinal degeneration phenotypes, such as autosomal recessive Stargardt disease (STGD), cone-rod dystrophy (CRD) and retinitis pigmentosa (RP). Different combinations of "mild", "moderate", and "severe" ABCA4 mutant alleles result in distinct phenotypes in a continuum of disease manifestations. Variation in the ABCA4 locus has emerged as the most prevalent cause of Mendelian retinal disease, with an estimated 1/20 people across all populations carrying a potential disease-associated variant in this gene. Clinical and allelic heterogeneity has substantially complicated genetic analyses of ABCA4-associated retinal disease. Direct sequencing of the entire ABCA4 open reading frame (ORF) currently detects up to 80% of the alleles, resulting in the identification of the 2 expected mutations in ~50% of patients, 1 mutation in 30%, while no disease-associated allele is found in the ABCA4 coding region in 20% patients. Since ABCA4 is the only known gene responsible for recessive STGD, it is clear that many disease- associated alleles must be located outside of the coding regions, especially in patients where 1 mutation is found in the ORF. The major goal of this proposal is to test the hypotheses that there are significant numbers of mutations in non-coding sequences of the ABCA4 genomic locus that contribute to ABCA4-associated disease load and that mutations in additional known and novel genes are responsible for the remainder of diseases with ABCA4-like phenotypes. To investigate these hypotheses, we will use our large clinical and genetic databases of sporadic and familial patients with ABCA4-associated diseases to determine all disease-associated variants in the entire ABCA4 locus on 1p21 by a step-by-step approach utilizing the next generation sequencing technologies and copy number variation (CNV) analyses. First, we will sequence the entire ABCA4 ORF in all patients with 1 mutation, followed by deep sequencing and CNV analyses of the entire ABCA4 genomic locus in these patients where no 2nd mutation will be found. After exhausting the ABCA4 locus analysis and confirming the variants by statistical and functional tests, we will determine what other genes are underlying ABCA4-like phenotypes in patients where no mutation is found in the ABCA4 locus by targeted resequencing of known loci, followed by full genome exome sequencing in selected families. The outcome of these studies will substantially aid in disease diagnosis, prognosis and will serve as a platform for selecting patients for emerging clinical trials geared to delay the onset, or arrest the progression, of ABCA4-associated diseases.
PUBLIC HEALTH RELEVANCE: Diseases caused by mutations in the ABCA4 gene represent a variety of autosomal recessive retinal degeneration phenotypes, including Stargardt disease (STGD), cone-rod dystrophy (CRD) and retinitis pigmentosa (RP); variation in the ABCA4 locus has emerged as the most prevalent cause of Mendelian retinal disease. Current mutation detection methods are able to identify 70-80% of all disease-causing alleles in the ABCA4 locus. Identification of all genetic variation in the ABCA4 locus by cutting-edge technologies, as suggested in this proposal, will substantially aid in disease diagnosis, prognosis and will serve as a platform for selecting patients for emerging clinical trials geared to delay the onset, or arrest the progression, of ABCA4- associated diseases.
描述(申请人提供):ABCA4基因突变导致多种视网膜变性表型,如常染色体隐性遗传性Stargardt病(STGD)、视锥-视杆细胞营养不良(CRD)和视网膜色素变性(RP)。“轻度”、“中度”和“重度”ABCA4突变等位基因的不同组合导致一系列疾病表现的不同表型。ABCA4基因的变异已成为孟德尔人视网膜疾病最常见的原因,估计在所有人群中,有1/20的人携带该基因潜在的疾病相关变异。临床和等位基因的异质性使ABCA4相关视网膜疾病的遗传分析变得非常复杂。目前,对整个ABCA4开放阅读框架(ORF)的直接测序可以检测到高达80%的等位基因,导致在~50%的患者中识别出2个预期的突变,在30%的患者中发现1个突变,而在20%的患者的ABCA4编码区中没有发现与疾病相关的等位基因。由于ABCA4是唯一已知的导致隐性STGD的基因,很明显,许多疾病相关等位基因必须位于编码区之外,特别是在ORF发现1个突变的患者中。这项建议的主要目标是检验以下假设,即ABCA4基因组座位的非编码序列中有大量突变导致ABCA4相关疾病负载,以及其他已知和新基因的突变是导致ABCA4样表型疾病的剩余原因的假设。为了研究这些假说,我们将使用我们的大型临床和遗传数据库,利用我们的散发性和家族性ABCA4相关疾病患者的数据库,通过利用下一代测序技术和拷贝数变异(CNV)分析,逐步确定1p21上整个ABCA4基因座的所有疾病相关变异。首先,我们将对所有有1个突变的患者的整个ABCA4 ORF进行测序,然后对这些患者的整个ABCA4基因组进行深度测序和CNV分析,在这些患者中不会发现第二个突变。在完成ABCA4基因座分析并通过统计和功能测试确认变异后,我们将通过对已知基因座进行有针对性的重新测序,然后在选定的家系中进行全基因组外显子组测序,确定在ABCA4基因座未发现突变的患者中,还有哪些基因是ABCA4样表型的潜在基因。这些研究的结果将大大有助于疾病的诊断和预后,并将成为为新的临床试验挑选患者的平台,这些临床试验旨在推迟或阻止ABCA4相关疾病的发病或进展。
公共卫生相关性:ABCA4基因突变引起的疾病表现为多种常染色体隐性遗传性视网膜变性表型,包括Stargardt病(STGD)、视锥-视杆细胞营养不良(CRD)和视网膜色素变性(RP);ABCA4基因突变已成为孟德尔视网膜疾病的最常见原因。目前的突变检测方法能够识别ABCA4基因座上70%-80%的致病等位基因。这项建议建议,通过尖端技术识别ABCA4基因座的所有遗传变异,将大大有助于疾病诊断和预后,并将成为选择患者进行新兴临床试验的平台,这些临床试验旨在延缓或阻止ABCA4相关疾病的发病或进展。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
RANDO L ALLIKMETS其他文献
RANDO L ALLIKMETS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('RANDO L ALLIKMETS', 18)}}的其他基金
Integrated clinical, genetic and functional analysis of the ABCA4 locus
ABCA4 基因座的综合临床、遗传和功能分析
- 批准号:
10636782 - 财政年份:2019
- 资助金额:
$ 65.96万 - 项目类别:
Integrated clinical, genetic and functional analysis of the ABCA4 locus
ABCA4 基因座的综合临床、遗传和功能分析
- 批准号:
10155493 - 财政年份:2019
- 资助金额:
$ 65.96万 - 项目类别:
Integrated clinical, genetic and functional analysis of the ABCA4 locus
ABCA4 基因座的综合临床、遗传和功能分析
- 批准号:
10382301 - 财政年份:2019
- 资助金额:
$ 65.96万 - 项目类别:
Precision medicine for ABCA4 disease: modifier alleles
ABCA4 疾病的精准医学:修饰等位基因
- 批准号:
10203998 - 财政年份:2018
- 资助金额:
$ 65.96万 - 项目类别:
Completing genetic analysis of the ABCA4 locus
完成 ABCA4 位点的遗传分析
- 批准号:
8658084 - 财政年份:2011
- 资助金额:
$ 65.96万 - 项目类别:
Therapeutic approaches for ABCA4-associated disorders
ABCA4 相关疾病的治疗方法
- 批准号:
8300072 - 财政年份:2011
- 资助金额:
$ 65.96万 - 项目类别:
Therapeutic approaches for ABCA4-associated disorders
ABCA4 相关疾病的治疗方法
- 批准号:
8018761 - 财政年份:2011
- 资助金额:
$ 65.96万 - 项目类别:
Therapeutic approaches for ABCA4-associated disorders
ABCA4 相关疾病的治疗方法
- 批准号:
8920581 - 财政年份:2011
- 资助金额:
$ 65.96万 - 项目类别:
Completing genetic analysis of the ABCA4 locus
完成 ABCA4 位点的遗传分析
- 批准号:
8245692 - 财政年份:2011
- 资助金额:
$ 65.96万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 65.96万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 65.96万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 65.96万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 65.96万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 65.96万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 65.96万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 65.96万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 65.96万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 65.96万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 65.96万 - 项目类别:
Research Grant